Multispecific PSMAxCD3 Antibodies for T Cell Redirection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective targeting and treatment mechanisms for prostate-specific membrane antigen (PSMA) expressing cells, particularly in prostate and renal cancers, as existing antibodies often have limited specificity and affinity, and bispecific antibodies that can redirect T cells to PSMA-expressing cells are not adequately developed.
Innovation Solution
Development of isolated antibodies and multispecific antibodies, such as PSMAxCD3 antibodies, with specific binding domains that target PSMA and CD3, enabling redirection of T cells to PSMA-expressing cells, thereby facilitating targeted therapy for prostate and renal cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibodies are used for PSMA targeting, then treatment can be provided, but the antibodies have limited specificity and affinity
Solution Approach 1:
The patent combines two antibody specificities into a single multispecific antibody molecule that can bind both PSMA on cancer cells and CD3 on T cells. This merging of functions allows the antibody to simultaneously engage target cells and redirect T cell cytotoxicity, resolving the limitation of existing single-specificity antibodies that lack sufficient effectiveness despite having basic binding capability.
Solution Approach 2:
The multisspecific antibody serves multiple functions: it acts as a targeting agent that binds PSMA with high affinity, a T cell redirector that engages CD3, and a bridge that physically connects T cells to cancer cells. This multi-functionality resolves the contradiction by providing both high specificity (through PSMA binding) and high effectiveness (through T cell redirection and activation).
2Adaptability or versatility
If bispecific antibodies are developed to redirect T cells, then targeted therapy is enabled, but adequate development and optimization are lacking
Solution Approach 1:
The patent optimizes the binding parameters of the multisspecific antibody by selecting and engineering antibody variable regions with specific properties. The heavy and light chain variable regions are chosen to provide optimal affinity for both PSMA and CD3, ensuring reliable binding performance while maintaining the versatility of T cell redirection capability.
3Measurement precision
If antibodies with high affinity for PSMA are created, then targeting precision is improved, but the complexity of antibody design and production increases
Solution Approach 1:
The multisspecific antibody is constructed by segmenting the antibody into distinct functional domains: a PSMA-binding domain composed of specific heavy and light chain variable regions, and a CD3-binding domain. This segmentation allows each domain to be optimized independently for its specific binding function while maintaining overall antibody stability and manufacturability.
Data Source
AI summary
Provided herein, in certain aspects, are antibodies that bind to PSMA, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to PSMA and CD3, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.